---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-23-000004"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:28:24.564173+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics highlights 2023 priorities: CTIM-76 candidate, ONA-XR data updates, cash runway into Q1 2024

## Summary
- CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody candidate; IND filing expected Q1 2024.
- ONA-XR Phase 2 endometrial cancer (OATH) shows 77% 4-month PFS rate; additional data expected mid-2023.
- ONA-XR Phase 2 breast cancer (SMILE) shows 44% 4-month PFS rate; additional data expected Q4 2023.
- ELONA Phase 1b/2 breast cancer trial with Menarini's elacestrant opened and enrolled first patient.
- Cash and equivalents $39.4M as of Sep 30, 2022; expected to fund operations into Q1 2024.

## SEC filing metadata
- accession: 0001842952-23-000004
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000004/0001842952-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000004/cntx-20230104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-23-000004
- JSON: https://secwatch.observer/filing/0001842952-23-000004.json
- Plain text: https://secwatch.observer/filing/0001842952-23-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.